---
layout: default
title: Inclisiran
parent: 僅模型預測 (L5)
nav_order: 230
evidence_level: L5
indication_count: 10
---

# Inclisiran
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the report template to produce the Evidence Pack-based report below.

# Inclisiran: From PCSK9-Targeted Lipid Therapy to Potassium Deficiency Disease

## One-Sentence Summary

Inclisiran is a small interfering RNA (siRNA) that silences PCSK9 mRNA in hepatocytes; the specific original indication text is not available in this Evidence Pack. The TxGNN model predicts a possible link to **Potassium Deficiency Disease** with a very high confidence score, but **no clinical trials and no literature** currently support this direction, and the evidence pack's own mechanistic review flags the prediction as a likely **false positive**.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in Evidence Pack (no `original_indications` or `original_moa` data provided; DrugBank record exists but MOA field is a data gap) |
| Predicted New Indication | Potassium deficiency disease |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 (model prediction only — no clinical trials or literature identified) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for Inclisiran is not available as a structured field in this Evidence Pack. However, the repurposing rationale text associated with this prediction identifies Inclisiran as an siRNA that targets PCSK9 mRNA, acting on hepatic lipoprotein metabolism.

Based on this mechanistic description, the Evidence Pack's own analysis concludes that there is **no known overlap** between the PCSK9/hepatic lipoprotein pathway and potassium homeostasis (renal handling, aldosterone axis, or potassium transporters). No literature was found supporting a connection between PCSK9 inhibition and renal tubular potassium regulation. The rationale explicitly characterizes this as **"a high-score prediction with no mechanistic link — a likely false positive."**

This assessment is reinforced by the pattern across all top-ranked predictions in this Evidence Pack: esophageal disease, non-syndromic esophageal malformation, atypical coarctation of the aorta, and migraine disorder are also ranked with very high TxGNN scores (99.8–99.9%), yet each carries the same mechanistic disclaimer — no plausible biological pathway connecting PCSK9-mediated lipid metabolism to these conditions, and zero supporting trials or publications for any of them. This suggests the high TxGNN scores in this candidate set may reflect a systematic scoring artifact rather than genuine biological signal, and each candidate should be interpreted with caution.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Denmark Market Information

No marketing authorisations are currently registered for Inclisiran in Denmark (market status: **Not marketed**, 0 licenses on file).

---

## Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

*Note: A blocking data gap exists — the Danish Medicines Agency (Laegemiddelstyrelsen) label warnings/contraindications have not yet been retrieved, which prevents this candidate from progressing to an initial (S1) safety review.*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- Evidence level is L5 — the prediction rests entirely on the TxGNN model score, with zero corroborating clinical trials or literature.
- The Evidence Pack's own mechanistic rationale argues **against** biological plausibility, explicitly labeling this as a probable false positive, and the same pattern repeats across all other top-ranked candidates for this drug.
- A blocking data gap (Danish SmPC warnings/contraindications) means this candidate cannot yet enter safety pre-screening (S1) regardless of predicted-indication strength.

**To proceed, the following is needed:**
- Retrieve Danish Medicines Agency (Laegemiddelstyrelsen) label warnings and contraindications (blocking gap, DG001)
- Retrieve verified mechanism of action data from DrugBank (DG002)
- Confirm the drug's actual original indication(s), currently missing from this Evidence Pack
- Independent mechanistic or preclinical evidence specifically linking PCSK9 mRNA silencing to potassium homeostasis, before any further investment in this candidate
- Given the consistent lack of mechanistic support across this drug's full candidate list, consider re-evaluating the TxGNN scoring output for this drug as a possible systematic artifact rather than evaluating each candidate individually
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

